← Leaderboards
Carly Jacquelyn Weddle
Northwestern University At Chicago
$126,121
Attributed
$126,121
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $42.9K · FY2021–23$50K$37.5K$25K$12.5K$0
'21
'22
'23
Funding mix
By agency
NIH$126,121 · 1
By mechanism
F31$126,121 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- Jacqueline Sara Jeruss$5,717,141
- Chonghui Cheng$7,932,847
- Francesca E. Duncan$6,656,849
- Suzanne Marie Schauwecker$190,260
- Seema Khan$8,985,480
Others in their field
Other Emerging Leaders on “Architecture”
- Arnab Kumar Chatterjee · Washington University$22,541,385
- Scott Topper · Broad Institute, Inc.$20,735,000
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Robert J Woods · Virginia Polytechnic Institute And State University$12,760,318
- John Otridge · Leidos Biomedical Research, Inc.$12,071,178
- Benedict Paten · University Of California Santa Cruz$11,912,519
Research focus
ArchitectureAffectBiological MarkersBiological ModelsBasic Cancer ResearchBrca GeneBrca MutationsBreast Cancer CellBreast Cancer Cell LineBreast Cancer ModelBreast Cancer PatientBreast Epithelial CellsBreast TumorigenesisCancer BiomarkersCancer CellCancer GenomeCareerCell Differentiation ProcessCell LineCell LineageCellsCell TypeCessation Of LifeChromosome Abnormality
Grant awards (3)
A patient-specific hiPSC model of breast cancer to identify genetic determinants of subclonal response and resistance to PARP inhibitors$42,907
F31 · FY2023 · CA · contact PI
A patient-specific hiPSC model of breast cancer to identify genetic determinants of subclonal response and resistance to PARP inhibitors$41,965
F31 · FY2022 · CA · contact PI
A patient-specific hiPSC model of breast cancer to identify genetic determinants of subclonal response and resistance to PARP inhibitors$41,249
F31 · FY2021 · CA · contact PI